Baidu
map

感染指南

订阅

MedSci主页 / 所有栏目 / 感染指南

2018 CASL指南：慢性丙型肝炎的管理（更新版）

2018-06-04 加拿大肝病学会 CMAJ 2018 June 4;190:E677-87.

慢性丙型肝炎

2018年6月，加拿大肝病学会(CASL)更新发布了慢性丙型肝炎的管理指南，慢性丙型肝炎是一个严重的公众健康问题，本文主要是对2015年版加拿大慢性丙肝管理指南的更新，主要目的是为临床卫生工作人员针对慢性丙肝感染患者的管理提出指导建议。

中文标题：

2018 CASL指南：慢性丙型肝炎的管理（更新版）

英文标题：

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

发布机构：

加拿大肝病学会

发布日期：

2018-06-04

简要介绍：

2018年6月，加拿大肝病学会(CASL)更新发布了慢性丙型肝炎的管理指南，慢性丙型肝炎是一个严重的公众健康问题，本文主要是对2015年版加拿大慢性丙肝管理指南的更新，主要目的是为临床卫生工作人员针对慢性丙肝感染患者的管理提出指导建议。 

拓展指南：与丙型肝炎相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 CASL指南：慢性丙型肝炎的管理（更新版）)] GetToolGuiderByIdResponse(projectId=1, id=c88531c001601033, title=2018 CASL指南：慢性丙型肝炎的管理（更新版）, enTitle=The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver, guiderFrom=CMAJ 2018 June 4;190:E677-87., authorId=null, author=, summary=2018年6月，加拿大肝病学会(CASL)更新发布了慢性丙型肝炎的管理指南，慢性丙型肝炎是一个严重的公众健康问题，本文主要是对2015年版加拿大慢性丙肝管理指南的更新，主要目的是为临床卫生工作人员针对慢性丙肝感染患者的管理提出指导建议。 , cover=, journalId=null, articlesId=null, associationId=98, associationName=加拿大肝病学会, associationIntro=加拿大肝病学会代表了加拿大所有致力于肝病研究的医生、科研工作者和健康服务机构，其目的在于提高健康服务水平，提供医学继续教育，促进肝病研究和学术交流，使加拿大肝病学会成为世界肝病领域的领导者。《Canada Journal of Gastroenterology》是其官方杂志。, copyright=0, guiderPublishedTime=Mon Jun 04 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年6月，加拿大肝病学会(CASL)更新发布了慢性丙型肝炎的管理指南，慢性丙型肝炎是一个严重的公众健康问题，本文主要是对2015年版加拿大慢性丙肝管理指南的更新，主要目的是为临床卫生工作人员针对慢性丙肝感染患者的管理提出指导建议。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>丙型肝炎</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=b02c01c001580945" title="2018 EASL建议：丙型肝炎的治疗" target=_blank>2018 EASL建议：丙型肝炎的治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=68bc71c001520e63" title="《世界胃肠病学组织全球指南：丙型肝炎的诊断、 管理和预防（2017年更新版）》解读分析" target=_blank>《世界胃肠病学组织全球指南：丙型肝炎的诊断、 管理和预防（2017年更新版）》解读分析</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=42ecf1c001505555" title="《2017年国际肝移植学会肝移植候选者丙型肝炎管理共识》摘译" target=_blank>《2017年国际肝移植学会肝移植候选者丙型肝炎管理共识》摘译</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=a78811c001a96538" title="2017 丙型肝炎治疗建议" target=_blank>2017 丙型肝炎治疗建议</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=adad11c001a51938" title="2017 WGO全球指南：丙型肝炎的诊断，管理和预防" target=_blank>2017 WGO全球指南：丙型肝炎的诊断，管理和预防</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E4%B8%99%E5%9E%8B%E8%82%9D%E7%82%8E" target=_blank>有关丙型肝炎更多指南</a></ul>, tagList=[TagDto(tagId=8528, tagName=慢性丙型肝炎)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5251, appHits=196, showAppHits=0, pcHits=3743, showPcHits=1852, likes=114, shares=2, comments=8, approvalStatus=1, publishedTime=Thu Jun 07 21:42:58 CST 2018, publishedTimeString=2018-06-04, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Jun 07 21:42:58 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:14:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 CASL指南：慢性丙型肝炎的管理（更新版）)])
2018 CASL指南：慢性丙型肝炎的管理（更新版）
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=350043, encodeId=415835004328, content=很好学习了！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/20/c3c2d5ecac5e792e100a6ba487b657f7.jpg, createdBy=8a972419003, createdName=神奇的印度(丙肝特效/肿瘤靶向), createdTime=Sun Oct 21 08:09:15 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325557, encodeId=0df232555ed8, content=学习了.谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 20 08:36:58 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325094, encodeId=71a9325094f4, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Mon Jun 18 08:07:36 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322820, encodeId=508332282057, content=这么厉害的技术.还是要仔细学习., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jun 09 15:23:58 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322463, encodeId=0477322463f9, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-10-21 神奇的印度(丙肝特效/肿瘤靶向)

    很好学习了！！！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=350043, encodeId=415835004328, content=很好学习了！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/20/c3c2d5ecac5e792e100a6ba487b657f7.jpg, createdBy=8a972419003, createdName=神奇的印度(丙肝特效/肿瘤靶向), createdTime=Sun Oct 21 08:09:15 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325557, encodeId=0df232555ed8, content=学习了.谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 20 08:36:58 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325094, encodeId=71a9325094f4, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Mon Jun 18 08:07:36 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322820, encodeId=508332282057, content=这么厉害的技术.还是要仔细学习., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jun 09 15:23:58 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322463, encodeId=0477322463f9, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-20 虈亣靌

    学习了.谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=350043, encodeId=415835004328, content=很好学习了！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/20/c3c2d5ecac5e792e100a6ba487b657f7.jpg, createdBy=8a972419003, createdName=神奇的印度(丙肝特效/肿瘤靶向), createdTime=Sun Oct 21 08:09:15 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325557, encodeId=0df232555ed8, content=学习了.谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 20 08:36:58 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325094, encodeId=71a9325094f4, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Mon Jun 18 08:07:36 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322820, encodeId=508332282057, content=这么厉害的技术.还是要仔细学习., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jun 09 15:23:58 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322463, encodeId=0477322463f9, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-18 zb1235672

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=350043, encodeId=415835004328, content=很好学习了！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/20/c3c2d5ecac5e792e100a6ba487b657f7.jpg, createdBy=8a972419003, createdName=神奇的印度(丙肝特效/肿瘤靶向), createdTime=Sun Oct 21 08:09:15 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325557, encodeId=0df232555ed8, content=学习了.谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 20 08:36:58 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325094, encodeId=71a9325094f4, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Mon Jun 18 08:07:36 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322820, encodeId=508332282057, content=这么厉害的技术.还是要仔细学习., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jun 09 15:23:58 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322463, encodeId=0477322463f9, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-09 虈亣靌

    这么厉害的技术.还是要仔细学习.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=350043, encodeId=415835004328, content=很好学习了！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/10/20/c3c2d5ecac5e792e100a6ba487b657f7.jpg, createdBy=8a972419003, createdName=神奇的印度(丙肝特效/肿瘤靶向), createdTime=Sun Oct 21 08:09:15 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325557, encodeId=0df232555ed8, content=学习了.谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jun 20 08:36:58 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325094, encodeId=71a9325094f4, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Mon Jun 18 08:07:36 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322820, encodeId=508332282057, content=这么厉害的技术.还是要仔细学习., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Jun 09 15:23:58 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322463, encodeId=0477322463f9, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-08 phoebeyan520

    认真学习.希望每天多一些新进展

    0

相关指南

2016 NICE技术评估指南：Elbasvir–grazoprevir用于治疗慢性丙型肝炎（TA413）

暂未更新 · 2016-10-26

Baidu
map
Baidu
map
Baidu
map